APLS vs. REGN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at APLS and REGN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
REGN’s market capitalization of 58.10 billion USD is significantly greater than APLS’s 2.29 billion USD, highlighting its more substantial market valuation.
APLS’s beta of 0.67 points to significantly higher volatility compared to REGN (beta: 0.31), suggesting APLS has greater potential for both gains and losses relative to market movements.
| Symbol | APLS | REGN |
|---|---|---|
| Company Name | Apellis Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| CEO | Cedric Francois | Leonard S. Schleifer |
| Price | 18.26 USD | 547.36 USD |
| Market Cap | 2.29 billion USD | 58.10 billion USD |
| Beta | 0.67 | 0.31 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | November 9, 2017 | April 2, 1991 |
| ADR | No | No |
Historical Performance
This chart compares the performance of APLS and REGN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
APLS
-100.06%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
APLS has a negative Return on Equity of -100.06%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
REGN
14.77%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
In the upper quartile for the Biotechnology industry, REGN’s Return on Equity of 14.77% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
APLS
-29.46%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
APLS has a negative Return on Invested Capital of -29.46%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
REGN
10.24%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
In the upper quartile for the Biotechnology industry, REGN’s Return on Invested Capital of 10.24% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
APLS
-28.83%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
APLS has a negative Net Profit Margin of -28.83%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
REGN
31.94%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
A Net Profit Margin of 31.94% places REGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
APLS
-24.00%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
APLS has a negative Operating Profit Margin of -24.00%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
REGN
27.37%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
An Operating Profit Margin of 27.37% places REGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | APLS | REGN |
|---|---|---|
| Return on Equity (TTM) | -100.06% | 14.77% |
| Return on Assets (TTM) | -27.71% | 11.98% |
| Return on Invested Capital (TTM) | -29.46% | 10.24% |
| Net Profit Margin (TTM) | -28.83% | 31.94% |
| Operating Profit Margin (TTM) | -24.00% | 27.37% |
| Gross Profit Margin (TTM) | 82.94% | 84.94% |
Financial Strength
Current Ratio
APLS
4.08
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
APLS’s Current Ratio of 4.08 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
REGN
4.93
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
REGN’s Current Ratio of 4.93 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
APLS
2.86
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
With a Debt-to-Equity Ratio of 2.86, APLS operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
REGN
0.09
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
REGN’s Debt-to-Equity Ratio of 0.09 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio
APLS
-4.19
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
APLS has a negative Interest Coverage Ratio of -4.19. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
REGN
98.59
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
REGN’s Interest Coverage Ratio of 98.59 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | APLS | REGN |
|---|---|---|
| Current Ratio (TTM) | 4.08 | 4.93 |
| Quick Ratio (TTM) | 3.62 | 4.03 |
| Debt-to-Equity Ratio (TTM) | 2.86 | 0.09 |
| Debt-to-Asset Ratio (TTM) | 0.58 | 0.07 |
| Net Debt-to-EBITDA Ratio (TTM) | -0.63 | -0.08 |
| Interest Coverage Ratio (TTM) | -4.19 | 98.59 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for APLS and REGN. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
APLS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
APLS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
REGN
0.16%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN’s Dividend Yield of 0.16% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
Dividend Payout Ratio
APLS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
APLS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
REGN
2.08%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 2.08%, REGN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
Dividend at a Glance
| Symbol | APLS | REGN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.16% |
| Dividend Payout Ratio (TTM) | 0.00% | 2.08% |
Valuation
Price-to-Earnings Ratio
APLS
-10.24
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
APLS has a negative P/E Ratio of -10.24. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
REGN
12.98
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
REGN’s P/E Ratio of 12.98 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
APLS
0.81
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
APLS’s Forward PEG Ratio of 0.81 is within the middle range of its peers in the Biotechnology industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
REGN
1.11
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
A Forward PEG Ratio of 1.11 places REGN in the upper quartile for the Biotechnology industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
Price-to-Sales Ratio
APLS
2.96
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
In the lower quartile for the Biotechnology industry, APLS’s P/S Ratio of 2.96 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
REGN
4.12
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
In the lower quartile for the Biotechnology industry, REGN’s P/S Ratio of 4.12 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio
APLS
13.95
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
REGN
1.99
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
Valuation at a Glance
| Symbol | APLS | REGN |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -10.24 | 12.98 |
| Forward PEG Ratio (TTM) | 0.81 | 1.11 |
| Price-to-Sales Ratio (P/S, TTM) | 2.96 | 4.12 |
| Price-to-Book Ratio (P/B, TTM) | 13.95 | 1.99 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -272.85 | 19.24 |
| EV-to-EBITDA (TTM) | -13.67 | 11.59 |
| EV-to-Sales (TTM) | 3.10 | 4.10 |